ECSP034453A - Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles - Google Patents

Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles

Info

Publication number
ECSP034453A
ECSP034453A EC2003004453A ECSP034453A ECSP034453A EC SP034453 A ECSP034453 A EC SP034453A EC 2003004453 A EC2003004453 A EC 2003004453A EC SP034453 A ECSP034453 A EC SP034453A EC SP034453 A ECSP034453 A EC SP034453A
Authority
EC
Ecuador
Prior art keywords
azoles
ullman
accelerated
anilinas
binding
Prior art date
Application number
EC2003004453A
Other languages
English (en)
Inventor
Hui Yin Li
Jia Cheng Zhou
Lucius T Rossano
Christopher A Teleha
Pasquale N Confalone
Charles G Clark
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP034453A publication Critical patent/ECSP034453A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Executing Machine-Instructions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee un método para la preparación de azoles fenil sustituidos. Este método emplea una eficiente reacción de acoplamiento Ullman ligando-acelerada de anilinas con azoles. Los productos de acoplamiento son útiles para preparar los inhibidores del factor Xa.
EC2003004453A 2000-07-26 2003-01-24 Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles ECSP034453A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22093200P 2000-07-26 2000-07-26

Publications (1)

Publication Number Publication Date
ECSP034453A true ECSP034453A (es) 2003-03-31

Family

ID=22825611

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004453A ECSP034453A (es) 2000-07-26 2003-01-24 Acoplamiento eficiente de ullman ligando-acelerada de anilinas y azoles

Country Status (22)

Country Link
US (1) US6541639B2 (es)
EP (1) EP1307431B1 (es)
JP (1) JP2004504384A (es)
KR (1) KR20030060872A (es)
CN (1) CN1444565A (es)
AT (1) ATE307804T1 (es)
AU (1) AU2001280813A1 (es)
BR (1) BR0112746A (es)
CA (1) CA2417426A1 (es)
DE (1) DE60114424T2 (es)
EC (1) ECSP034453A (es)
ES (1) ES2251501T3 (es)
HU (1) HUP0301699A3 (es)
IL (1) IL153547A0 (es)
IS (1) IS6695A (es)
MX (1) MXPA03000686A (es)
NO (1) NO20030393L (es)
NZ (1) NZ523271A (es)
PL (1) PL361233A1 (es)
RU (1) RU2003103706A (es)
WO (1) WO2002008199A2 (es)
ZA (1) ZA200300039B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266112C (zh) * 2001-04-24 2006-07-26 麻省理工学院 铜－催化的碳－杂原子键和碳－碳键的形成
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
CA2487475A1 (fr) * 2002-05-31 2003-12-11 Rhodia Chimie Procede de formation d'une liaison carbone-carbone ou carbone-heteroatome
CN1684944A (zh) 2002-08-02 2005-10-19 麻省理工学院 铜催化形成碳－杂原子和碳－碳键的方法
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
WO2006009431A1 (en) * 2004-07-16 2006-01-26 Dsm Ip Assets B.V. Process for the preparation of an (hetero)arylamine
CA2679754C (en) 2007-03-12 2018-08-07 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
JP2015514135A (ja) 2012-04-14 2015-05-18 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
DK2968320T3 (da) 2013-03-15 2021-02-01 Intra Cellular Therapies Inc Organiske forbindelser
CA3148303C (en) 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
CA2944512C (en) 2014-04-04 2018-04-24 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines for treatment of central nervous system disorders
WO2015171951A1 (en) * 2014-05-07 2015-11-12 The Regents Of The University Of Colorado, A Body Corporate 2-(4-aryl-1h-imidazol-1-yl)aniline compounds
PT3407888T (pt) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
SI3407889T1 (sl) 2016-03-25 2021-09-30 Intra-Cellular Therapies, Inc. Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
JP7223742B2 (ja) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
IL277504B1 (en) 2018-03-23 2026-02-01 Intra Cellular Therapies Inc Deuterium-converted ((sa10,rb6)-8-(3-(4-fluorophenoxy)propyl 6b, 7, 8, 9, 10, 10a-hexahydro-1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-82(h3)-one compounds, pharmaceutical composition containing them and their uses
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
DK3609891T3 (da) 2018-06-11 2026-02-23 Intra Cellular Therapies Inc Syntese af substituerede heterocykliske fusionerede gamma-carboliner
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
EP3898580A4 (en) 2018-12-17 2022-08-10 Intra-Cellular Therapies, Inc. SYNTHESIS OF CONDENSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLE
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372658A (ja) 1986-09-17 1988-04-02 Sumitomo Chem Co Ltd ニトロジフエニルアミン類の製造方法
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.

Also Published As

Publication number Publication date
EP1307431A2 (en) 2003-05-07
WO2002008199A2 (en) 2002-01-31
BR0112746A (pt) 2003-09-09
EP1307431B1 (en) 2005-10-26
IS6695A (is) 2003-01-22
US6541639B2 (en) 2003-04-01
JP2004504384A (ja) 2004-02-12
HUP0301699A2 (hu) 2003-12-29
WO2002008199A3 (en) 2002-06-13
RU2003103706A (ru) 2004-08-10
ZA200300039B (en) 2004-04-02
MXPA03000686A (es) 2003-06-06
PL361233A1 (en) 2004-10-04
CA2417426A1 (en) 2002-01-31
DE60114424D1 (de) 2005-12-01
ATE307804T1 (de) 2005-11-15
US20020099225A1 (en) 2002-07-25
AU2001280813A1 (en) 2002-02-05
CN1444565A (zh) 2003-09-24
NZ523271A (en) 2005-01-28
HUP0301699A3 (en) 2004-03-29
KR20030060872A (ko) 2003-07-16
ES2251501T3 (es) 2006-05-01
DE60114424T2 (de) 2006-07-27
NO20030393D0 (no) 2003-01-24
IL153547A0 (en) 2003-07-06
NO20030393L (no) 2003-03-24

Similar Documents

Publication Publication Date Title
NO20030393L (no) Effektiv ligand-mediert Ullmann-kobling av aniliner og azoler
CY1109276T1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
CR20140277A (es) Derivados de azaadamantano y métodos de uso de los mismos
ES2141688B1 (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
AR019507A1 (es) Uso de los inhibidores de cyp2d6 en terapias de combinacion
YU5503A (sh) Nesteroidni supresori zapaljenja
CY1106743T1 (el) Μεθοδος παρασκευης θειαμεθοξαμης
ATE429901T1 (de) Selbstformende thermodynamisch stabile liposome
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
ATE359431T1 (de) Vorrichtung und verfahren zur elektrischen kupplung
GB0011358D0 (en) Novel use
UY26675A1 (es) Sales de imidazo-3-aminas e imidazo-5-aminas bicíclicas n-aciladas y sus productos de adicción con ácidos, procedimientos para su preparación y medicamentos que contienen estos compuestos
ITMI20022214A1 (it) Procedimento per produrre una soluzione di cellulosa altamente omogenea.
NO20032241D0 (no) Forbedret prosess for vannlöselige azolforbindelser
BR0212153A (pt) Compostos e respectivos processos de preparação e de isolamento de dicloreto de 2-difluormetilornitina
UY26556A1 (es) Compuestos calcilíticos
NO20025264L (no) Reduktiv alkyleringsprosess
NO20032558D0 (no) Fremgangsmåte for fremstilling av paklitaxel
DE10193598T1 (de) Schutzvorrichtung für eine Stromquelle zur Versorgung einer elektrischen Einrichtung
AR022905A1 (es) Un procedimiento para preparar ciclo(asp-dfen-nmeval-arg-gli) y los pentapeptidos lineales que son productos intermedios en este procedimiento.
IT1307355B1 (it) Apparato per la generazione di una frequenza di riferimento.
ECSP003848A (es) Inhibidores de la proteinasa del c del procolageno
DE60232650D1 (de) Peptiddeformylaseinhibitoren
IT1319660B1 (it) Processo per la preparazione di 1-(1-amminoalchil)ossirani protetti.